Industry Insight | European Biotechs Accelerate Development of Next-Generation CGT Manufacturing Technologies

May 2026 - European biotechnology companies are increasing investment in next-generation manufacturing technologies as the cell and gene therapy (CGT) industry shifts toward large-scale commercialization and industrialized production models.

According to a recent industry analysis published by Pharmaceutical Technology, European CGT developers are focusing heavily on automation, decentralized manufacturing, closed-system production, and scalable viral vector capacity to address growing demand for advanced therapies.

The report notes that manufacturing costs remain one of the largest barriers to broader adoption of cell therapies. For CAR-T therapies, manufacturing expenses alone can exceed €60,000 per patient, while global production capacity continues to lag behind market demand.

Photo by Trnava University on Unsplash 

To address these challenges, several European biotech companies are developing new manufacturing platforms and infrastructure strategies:

· Ori Biotech is advancing closed-loop automated manufacturing systems designed to support decentralized cell therapy production.

· Oxford Biomedica continues expanding lentiviral vector manufacturing capabilities across Europe.

· Touchlight is scaling enzymatic synthetic DNA manufacturing technologies aimed at improving scalability and reducing contamination risk.

· TreeFrog Therapeutics is developing bioreactor-based stem cell expansion technologies for large-scale regenerative medicine manufacturing.

Industry analysts note that the sector is increasingly transitioning from a research-focused phase toward a manufacturing-driven phase, where scalability, reproducibility, and cost efficiency are becoming key competitive factors.

The report also highlights growing industry interest in:

· Automated closed-system workflows

· AI-assisted manufacturing analytics

· Decentralized production models

· GMP standardization

· Scalable immune-cell expansion platforms

Photo by Logan Gutierrez on Unsplash

As more CAR-T, CAR-NK, and regenerative medicine therapies move closer to commercialization, enabling technologies that support efficient and reproducible cell expansion are expected to become increasingly important across the broader CGT ecosystem.

Companies such as Hillgene Biopharma are contributing to this trend through engineered K562 feeder-cell platforms designed to support NK and CAR-NK cell expansion workflows.

Source: Pharmaceutical Technology – “European Biotechs Developing Next-Generation Cell and Gene Therapy Manufacturing Technologies” (Published May 22, 2026)